1,060 results on '"Vermorken, Jan B"'
Search Results
52. Gynecologic Cancer
53. Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
54. Estimating the Prevalence of a True Oligometastatic Disease
55. Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
56. Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases
57. Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab
58. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies
59. Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond
60. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
61. Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone
62. When is chemotherapy in head and neck squamous cell carcinoma not indicated?
63. Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization
64. Prognostic implications of cellular senescence in resected non-small cell lung cancer
65. The “Make Sense Campaign”: An Initiative of the European Head and Neck Society
66. Patient and Treatment Factors in Concurrent Chemoradiotherapy
67. Multidisciplinary Decision Making and Head and Neck Tumor Boards
68. Immunotherapeutic Approaches
69. Treatment in the Elderly
70. Human Papillomavirus (HPV): A Criterion for Therapeutic Decision in Squamous Cell Carcinoma of the Head and Neck?
71. Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
72. Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era
73. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
74. Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
75. ISY5-1 - Recurrent or metastatic disease
76. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review
77. General principles of head and neck cancer management
78. Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid
79. Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?
80. Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research
81. Concentration and Time Dependent Growth Inhibition and Metabolism in vitro by 2’,2’-Difluoro-Deoxycytidine (Gemcitabine)
82. Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era
83. RADIOTHERAPY, GEMCITABINE, AND CETUXIMAB (RAGE) AFTER INDUCTION CHEMOTHERAPY (ICT) IS A MANAGEABLE AND PROMISING THERAPY FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LASCCHN).: OP002.
84. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data
85. Current concepts for the management of head and neck cancer: Chemotherapy
86. Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model
87. Estimating the Prevalence of a True Oligometastatic Disease.
88. Preface
89. Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer
90. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
91. Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes
92. Electrochemotherapy in mucosal cancer of the head and neck
93. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
94. Detection of Microsatellite Instability in Colorectal Cancer Using an Alternative Multiplex Assay of Quasi-Monomorphic Mononucleotide Markers
95. Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population
96. Induction Therapy in the Modern Era of Combined-Modality Therapy for Locally Advanced Head and Neck Cancer
97. Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate
98. Ductal carcinoma in situ: a challenging disease
99. Overcoming frailty in recurrent and metastatic head and neck cancer
100. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.